Opus Genetics, Inc. Cash Flow Conversion Efficiency
Opus Genetics, Inc. cash flow conversion efficiency. Based on the latest financial reports, Opus Genetics, Inc. (IRD) has a cash flow conversion efficiency ratio of 0.920x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.95 Million) by net assets ($-12.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Opus Genetics, Inc. (2019–2025)
Cash flow conversion efficiency of Opus Genetics, Inc. from 2019 to 2025. This chart illustrates how Opus Genetics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View IRD live share price for real-time trading data and today's change.
Opus Genetics, Inc. Cash Flow Conversion Ratio Explained
Opus Genetics, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Opus Genetics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Opus Genetics, Inc. ranked by their cash flow conversion efficiency. Also see IRD company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Longli Technology Co Ltd Class A
SHE:300752
|
0.018x |
|
Zhejiang Double Arrow Rubber Co Ltd
SHE:002381
|
0.067x |
|
Tiv Taam
TA:TTAM
|
0.162x |
|
Aurora Cannabis Inc
TO:ACB
|
-0.008x |
|
indie Semiconductor Inc
NASDAQ:INDI
|
-0.090x |
|
Malaysia Smelting Corporation Bhd
KLSE:5916
|
0.133x |
|
i3 Verticals Inc
NASDAQ:IIIV
|
0.036x |
|
QC Solar (Suzhou) Co. Ltd. A
SHE:301278
|
0.010x |
Annual Cash Flow Conversion Efficiency for Opus Genetics, Inc. (2019–2025)
The table below shows the annual cash flow conversion efficiency of Opus Genetics, Inc. from 2019 to 2025. Review Opus Genetics, Inc. (IRD) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.35 Million | $-35.25 Million | -2.297x | +39.61% |
| 2024-12-31 | $6.72 Million | $-25.58 Million | -3.804x | -16970.76% |
| 2023-12-31 | $49.91 Million | $-1.11 Million | -0.022x | -107.20% |
| 2022-12-31 | $46.24 Million | $14.31 Million | 0.310x | +135.51% |
| 2021-12-31 | $22.22 Million | $-19.37 Million | -0.872x | -272.70% |
| 2020-12-31 | $-13.47 Million | $-6.80 Million | 0.505x | +6.20% |
| 2019-12-31 | $-7.56 Million | $-3.59 Million | 0.475x | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more